Trials / Terminated
TerminatedNCT05349435
A Healthy Volunteer Study to Compare Fezagepras (PBI-4050) With Sodium Phenylbutyrate
A Phase 1, Randomised, Open-Label, Crossover Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Ascending Doses of PBI-4050 Compared to Sodium Phenylbutyrate in Healthy Subjects
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 8 (actual)
- Sponsor
- Liminal BioSciences Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to compare the safety, tolerability and pharmacokinetic profile of fezagepras (PBI-4050) to that of sodium phenylbutyrate (PBA) when both products are given as single ascending doses to healthy adult subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Fezagepras | Investigational drug |
| DRUG | Sodium phenylbutyrate | Investigational drug |
Timeline
- Start date
- 2022-05-13
- Primary completion
- 2022-06-30
- Completion
- 2022-06-30
- First posted
- 2022-04-27
- Last updated
- 2022-08-01
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT05349435. Inclusion in this directory is not an endorsement.